2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Benjamin Miron, MD, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.
Benjamin Miron, MD, fellow, Hematology/Oncology, Fox Chase Cancer Center, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.
Treatment with FGFR inhibitors can lead to the emergence of several mutations that promote resistance, Miron says. Although there is not much known about these mutations, data from the use of FGFR inhibitors in biliary cancers have shed some light on some resistance mechanisms, Miron explains. These resistance mutations are similar to those that have been observed with other TKIs, such as EGFR inhibitors, Miron adds.
There are currently no approved agents that can target resistance mechanisms to FGFR inhibitors; however, drugs are under development to fill this unmet need, Miron adds. Without approved drugs, the current standard for patients who develop such mutations during treatment with an FGFR inhibitor is to switch therapies or to enroll to a clinical trial, Miron concludes.
Related Content: